Tecnología para la monitorización y control de Diabetes

SYSTEMS, DEVICES, AND METHODS TO COMPENSATE FOR TEMPERATURE EFFECTS ON SENSORS

Resumen de: US20260047785A1

This document discusses, among other things, systems and methods to compensate for the effects of temperature on sensors, such as analyte sensor. An example method may include determining a temperature-compensated glucose concentration level by receiving a temperature signal indicative of a temperature parameter of an external component, receiving a glucose signal indicative of an in vivo glucose concentration level, and determining a compensated glucose concentration level based on the glucose signal, the temperature signal, and a delay parameter.

WEARABLE TRANSPLANTABLE TISSUE VIABILITY BIOSENSOR

Resumen de: US20260047780A1

Disclosed are miniaturized, wearable microneedle biosensor devices, systems, and methods for measuring intradermal concentrations of various metabolites (including but not limited to lactate, pyruvate, and/or glucose) in order to directly assess the viability of living tissue (e.g., human or other mammalian soft tissue). In a variety of implementations, for example, the disclosed microneedle biosensor devices are self-contained in terms of power source, sample acquisition, measurement, and data transmission capabilities, e.g., allowing it to function autonomously once placed. In some implementations, for example, the disclosed microneedle biosensor devices can assess the viability of soft tissue (e.g., skin with or without fat, fascia, or muscle) during and after reconstructive surgery in which soft tissue is repositioned, rotated, or transferred to another site in the body (including but not limited to both microvascular free tissue transfer and regional pedicled flaps).

POROUS MICRONEEDLE ARRAY-BASED INTERSTITIAL FLUID GLUCOSE DETECTION DEVICE, METHOD OF PREPARING POROUS MICRONEEDLE ARRAY WITH POROSITY GRADIENT, AND METHOD OF PREPARING COLORIMETRIC FILM

Resumen de: US20260047781A1

A porous microneedle array-based interstitial fluid glucose detection device includes a microneedle module, a colorimetric detection module, an electrochemical detection module, and a liquid transport layer. The microneedle module includes a porous microneedle array with a porosity gradient, the porosity gradually increases from the needle tip to the microneedle substrate; the porous microneedle array penetrates human epidermis and extract interstitial fluid, which is then transferred to both the colorimetric detection module and the electrochemical detection module via the liquid transport layer. Within the colorimetric detection module, glucose undergoes a reaction with the color on the colorimetric film, resulting in color development that enables rapid glucose detection; In the electrochemical detection module, glucose undergoes a redox reaction on the working electrode, resulting in the generation of a current signal for the accurate detection of glucose.

BLOOD GLUCOSE ESTIMATION USING NEAR INFRARED LIGHT EMITTING DIODES

Resumen de: AU2026200301A1

Abstract Near Infrared Spectroscopy is employed to non-invasively detect blood glucose concentrations, in a multi-sensing detection device. A multi-layered artificial neural network is used to assess these relationships of non-linear interference from human tissue, as well as differences among individuals, and accurately estimate blood glucose levels. Diffuse reflectance spectrum from tlle palm at six different wavelengths analyzed with a neural network, results in a correlation coefficient as high as 0. 9216 when compared to a standard electrochemical glucose analysis test.

DEVICE FOR DELIVERING INSULIN HAVING FILM AND TOP ENCLOSURE DEFINING RESERVOIR

Resumen de: US20260048196A1

A device is disclosed for delivering medication to a user. The device comprises first and second enclosures that together form a housing of the device, the housing configured to house a reservoir for storing the medication, wherein the first enclosure includes an inner wall of the housing; and a film joined to the inner wall of the first enclosure, wherein the film and the inner wall of the first enclosure are configured to form walls of the reservoir for storing the medication.

DRUG DELIVERY DEVICE WITH INTEGRATED OPTICAL-BASED GLUCOSE MONITOR

Resumen de: EP4696344A2

Embodiments of the present disclosure relate to approaches for more efficiently measuring glucose levels using a wearable drug delivery device. In some embodiments, the wearable drug delivery device may include a needle deployment component including a cannula and an optical conduit deployable into a user, the cannula operable to deliver a liquid drug to the user. The wearable drug delivery device may further include a glucose monitor including an optical sensor, the optical sensor operable to measure a light output received via the optical conduit.

SYSTEMS AND METHODS FOR MONITORING AND TREATING DIABETIC FOOT ULCERS

Resumen de: EP4696226A2

In some aspects, a computer-implemented method is disclosed for gathering and processing sensor data to identify a risk of impacting or causing a skin injury. The computer-implemented method can include: receiving, via a computer network, sensor feature data representing output of a user sensor configured to be worn on a limb of a user; generating activity classification model output data using the sensor feature data and an activity classification model, the activity classification model output data representing likelihoods that the sensor feature data corresponds to each of a plurality of different activity classifications; determining an activity classification from the activity classification model output data; and transmitting, via the computer network, display data representing the activity classification to a computing device configured to present the display data.

SYSTEMS AND METHODS FOR CONTINUOUS GLUCOSE MONITORING OUTCOME PREDICTIONS

Resumen de: AU2024252061A1

Methods and devices include predicting future glucose and engagement levels for a user by receiving the user's glucose levels collected by a continuous glucose monitoring (CGM) device over a time period, receiving engagement data associated with the user, wherein the engagement data are associated with the user's medication intake, diet, physical activity, laboratory results, and education activity, determining a first glycemia risk index (GRI) value, determining, using a machine learning model and responsive to the user's glucose levels and the engagement data collected over the time period, one or more predictions for future glucose levels for the user including a prediction that a future GRI value is greater than or less than the first GRI value, and determining, using the machine learning model and responsive to the user's engagement data collected over the time period, one or more predictions for future engagement levels.

NON-INTRUSIVE, NEEDLE-FREE DETECTION OF THE SEVERE HYPOGLYCEMIA ONSET

Resumen de: US20260041379A1

Method for non-intrusive, needle-free detection of severe hypoglycemia onset through assessment of the cerebral arteriovenous oxygen difference. The method primarily pertains to the treatment of high-risk younger patients with Type 1 Diabetes Mellitus (T1DM) experiencing nocturnal hypoglycemia in order to prevent so called “Death in Bed” syndrome-the sudden death of young diabetic patients without any history of long-term complications.

CELL THERAPY FOR PATIENTS

Resumen de: US20260041337A1

Materials and methods of treating a patient with type 2 diabetes mellitus, metabolic syndrome, obesity, infertility, high blood pressure, hyperthyroidism, and hypothyroidism, hyperlipidaemia, osteoporosis, osteoarthritis, hypoadrenalism, polycystic ovary syndrome, or Parkinson's disease comprising administering a therapeutically effective amount of ex vivo cultured activated peripheral blood mononuclear cells (PBMCs) to the patient. The ex vivo cultured activated cells are activated and cultured in a presence of a cytokine and may be autologous or allogeneic relative to the patient.

Apparatus and Method for Taking Blood Glucose Measurements and Recommending Insulin Doses

Resumen de: US20260041338A1

The present disclosure related to an apparatus that may be used for taking blood glucose measurements and providing individualized insulin dose recommendations wherein the apparatus is easy to use and facilitates improved diabetes control in patients. Also disclosed are related methods.

METHOD OF SENSOR-LESS PLUNGER DETECTION DURING INSULIN RESERVOIR SETUP

Resumen de: US20260041843A1

A processor-implemented method includes obtaining motor rotation data associated with a motor that is configured to rotate steadily to actuate a drive system for driving a plunger of a reservoir in a fluid delivery device; for each rotation of a plurality of rotations of the motor, based on a measured rotation time of the rotation of the motor and a previous maximum rotation time of the motor, determining a current maximum rotation time of the motor and storing the current maximum rotation time in a buffer; determining a coefficient of variation of motor rotation time based on data in the buffer; determining a change of the coefficient of variation of motor rotation time with respect to a baseline coefficient of variation of motor rotation time; and determining whether the plunger is detected based on a comparison of the change and a threshold value.

METHOD OF COMPENSATING FOR INSULIN RESERVOIR FRICTION DURING INSULIN THERAPY

Resumen de: US20260041847A1

A processor-implemented method includes obtaining motor rotation data associated with a motor that is configured to rotate in strokes to drive a plunger within a reservoir in a fluid delivery device, the motor rotation data indicating time intervals between changes of position of the motor; for each stroke of a first plurality of strokes of the motor, determining an instantaneous delivery rate during one or more steps of the stroke based on the motor rotation data, and storing the instantaneous delivery rate to a buffer; determining a pre-compensation delivery rate of the fluid delivery device based on data in the buffer; and determining, in response to the pre-compensation delivery rate being lower than a pre-determined delivery rate, a first adjustment to at least one of a motor drive voltage level or a motor drive duty cycle of a drive signal of the motor.

NON-INVASIVE BIOSIGNAL MEASUREMENT DEVICE AND METHOD BASED ON SKIN EFFECT REMOVAL

Resumen de: US20260041375A1

A non-invasive biosignal measurement device based on skin effect removal, includes: a signal measurement instrument measuring a PPG signal of a measurement subject in contact with the skin on one side of a specific body part of the measurement subject; a signal reception unit receiving the PPG signal from the signal measurement instrument; and a ratio value calculation unit removing noise due to a skin effect from the PPG signal, and then calculating ratio values at different wavelengths for measuring a biosignal including blood sugar and glycated hemoglobin of the measurement subject. The signal measurement instrument includes a first sensor module including an optical barrier and a second sensor module for removing the skin effect.

METHOD FOR CONTINUOUSLY MEASURING BLOOD GLUCOSE USING A SENSOR MODULE, AND MEDICAL DEVICE MANAGEMENT SYSTEM USING THE SAME

Resumen de: WO2026034834A1

Disclosed is a sensor module management system comprising a sensor module including a transcutaneous analyte sensor configured to perform a measurement indicating an analyte level and a sensor electronics unit communicatively connected to the transcutaneous analyte sensor, and a mobile device configured to wirelessly communicate with the sensor electronics unit. The sensor module is configured to, when it is confirmed that a command array included in a sub-advertisement event received from the mobile device includes a first command designating a group ID to which the sensor module belongs and a device ID of the sensor module, transmit a first response to the mobile device in response to the first command. The first response includes the analyte level.

CONTINUOUS BLOOD GLUCOSE MEASUREMENT APPARATUS

Resumen de: EP4656127A2

The present invention relates to a continuous blood glucose measurement apparatus which, by manufacturing a body-attachable unit in an assembled state inside an applicator, minimizes the additional work by a user for attaching the body-attachable unit to the body and thus enables the body-attachable unit to be attached to the body simply by means of operating the applicator, and, by providing a wireless communication chip on the body-attachable unit and enabling communication with an external terminal, can be used in a simple and convenient manner without the additional work of connecting a separate transmitter and enables easier maintenance and management, and, by having the operation of the body-attachable unit initiated by means of the user's manipulation after being attached to the body, enables the operation initiation point to be adjusted to an appropriate point as necessary by the user, enables an operation initiation in a stabilized state and thus enables more accurate blood glucose measurement.

COMPUTER-IMPLEMENTED METHODS FOR PREDICTING GLUCOSE VALUES, DATA PROCESSING SYSTEM, MEDICAL SERVER, AND USER DEVICE

Resumen de: US20260013801A1

Methods for predicting glucose values which involve determining a predicction time window using historical data indicative of glucose level influencing events of a person having diabetes and at least one predicted glucose level influencing event. Further disclosed are data processing systems for predicting glucose values, medical servers, user devices, and computer programs.

COMPUTER-IMPLEMENTED METHODS FOR PREDICTING GLUCOSE VALUES, DATA PROCESSING SYSTEM, AND APP

Resumen de: US20260013800A1

A computer-implemented method and system for predicting and displaying glucose values, including receiving CGM data, determining, based on the data, a plurality of first predicted glucose values (33) for a first prediction time window (30), determining, based on the data, that a hypoglycemia event is predicted to occur during a second prediction time window (31) which has a contemporaneous beginning with the first prediction time window (30) but is shorter than the first window (30), and determining a plurality of second predicted glucose values (34) for the second prediction time window (31) and displaying the plurality of second predicted glucose values (34) for the second prediction time window (31) while not displaying predicted glucose values subsequent to the second prediction time window (31).

MANAGEMENT PROCESS FOR INSULIN THERAPY USING REINFORCEMENT LEARNING AND THERAPY ESCALATION PATHWAYS

Resumen de: AU2024252324A1

A method of therapy escalation for patients with diabetes includes receiving glucose data of a user from an in vivo glucose monitoring device, receiving first therapy information of a first therapy, wherein the first therapy includes basal insulin, calculating one or more glucose metrics based on the received glucose data, titrating a dose of the basal insulin based on the one or more glucose metrics, and determining overbasalization based on one or more of the glucose data and the first therapy information. Advantageously the system can regularly monitor glucose control of a user, detect overbasalization, provide frequent therapy intervention and adjustment, decrease a duration of intervention, and increase user adherence, outcomes, and satisfaction.

METHOD OF SENSOR-LESS PLUNGER DETECTION DURING INSULIN RESERVOIR SETUP

Resumen de: EP4691517A1

A processor-implemented method includes obtaining motor rotation data associated with a motor that is configured to rotate steadily to actuate a drive system for driving a plunger of a reservoir in a fluid delivery device; for each rotation of a plurality of rotations of the motor, based on a measured rotation time of the rotation of the motor and a previous maximum rotation time of the motor, determining a current maximum rotation time of the motor and storing the current maximum rotation time in a buffer; determining a coefficient of variation of motor rotation time based on data in the buffer; determining a change of the coefficient of variation of motor rotation time with respect to a baseline coefficient of variation of motor rotation time; and determining whether the plunger is detected based on a comparison of the change and a threshold value.

METHOD OF COMPENSATING FOR INSULIN RESERVOIR FRICTION DURING INSULIN THERAPY

Resumen de: EP4693324A1

A processor-implemented method includes obtaining motor rotation data associated with a motor that is configured to rotate in strokes to drive a plunger within a reservoir in a fluid delivery device, the motor rotation data indicating time intervals between changes of position of the motor; for each stroke of a first plurality of strokes of the motor, determining an instantaneous delivery rate during one or more steps of the stroke based on the motor rotation data, and storing the instantaneous delivery rate to a buffer; determining a pre-compensation delivery rate of the fluid delivery device based on data in the buffer; and determining, in response to the pre-compensation delivery rate being lower than a pre-determined delivery rate, a first adjustment to at least one of a motor drive voltage level or a motor drive duty cycle of a drive signal of the motor.

DETERMINING A CONCENTRATION OF GLUCOSE IN A SUBJECT'S BLOOD

Resumen de: AU2024313070A1

According to an aspect, there is provided a computer-implemented method (200) of determining a concentration of glucose in a subject's blood, the method comprising: acquiring (202) first measurement data indicative of a response resulting from an electromagnetic (EM) signal interacting with the subject's blood in a body part of the subject; acquiring (204) second measurement data indicative of at least one parameter associated with the subject; and using (206) a predictive model to infer a concentration of glucose in the subject's blood from the first measurement data and the second measurement data, the predictive model having been trained to infer a concentration of glucose in the subject's blood from the first measurement data and the second measurement data.

BASAL RATE TESTING USING FREQUENT BLOOD GLUCOSE INPUT

Resumen de: US20260034300A1

An apparatus comprising a user interface configured to generate an electrical signal to start a basal insulin rate test when prompted by a user, an input configured to receive sampled blood glucose data of a patient that is obtained during a specified time duration, including a time duration during delivery of insulin according to a specified basal insulin rate pattern, and a controller communicatively coupled to the input and the user interface. The controller includes an insulin calculation module configured for determining at least one of an amount of basal insulin over-delivered and an amount of basal insulin under-delivered during the basal insulin rate test in trying to meet a target blood glucose baseline. Other devices and methods are disclosed.

METHOD AND SYSTEM FOR GLYCEMIC PREDICTION AND DYNAMIC VISUALIZATION

Resumen de: US20260033753A1

Disclosed herein are system, method, and computer program product embodiments for interconnecting a prediction visualization with user medical data for analyzing the impact of personal choices on future glucose levels. The prediction visualization is configured to generate predictions of glycemic impact based one or more inputs including choices involving diet and exercise and user medical data, such as the user's historical and current glucose levels. The prediction visualization is configured to be adjustable based on user input and the visualization is configured to dynamically update based on user input. The disclosed interface allows the user to adjust the sequencing of these decisions and portion sizes of meal choices and immediately generate new visualizations representing the impact on predicted future glucose levels.

FLUID DELIVERY DEVICE HAVING MULTIPLE PENETRATING ELEMENTS

Nº publicación: US20260034298A1 05/02/2026

Solicitante:

INSULET CORP [US]
INSULET CORPORATION

Resumen de: US20260034298A1

Methods and apparatuses for performing an insertion process for a plurality of penetrating elements are described. For example, a wearable fluid infusion device may include a cannula and/or needle for infusing a fluid into a patient and a sensor for sensing a physical characteristic of the patient. A non-limiting example of a fluid may be or may include insulin. An illustrative and non-restrictive example of a physical characteristic may include a blood glucose level. The wearable infusion device may be configured to facilitate insertion of the multiple penetrating elements, such as a cannula and a sensor, in a single simultaneous insertion step instead of requiring individual insertion steps for each of multiple penetrating elements. Other embodiments are described.